Study study type PathologyT1T0Patientssample sizesROB Results

Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)

versus placebo
nivolumab alone
CheckMate 451 (N ; all population), 2019
  NCT02538666
RCTExtensive stage SCLC (Es-SCLC) - maintenance (M)nivolumabplacebopatients with extensive-stage disease small cell lung cancer (ED-SCLC) as maintenance therapy after completion of platinum-based chemotherapy280 / 275some concern
inconclusive
  • suggested 33 % decrease in progression or deaths (PFS)